Trials / Completed
CompletedNCT01963182
Individualization of Dosage of Irinotecan in the FOLFIRI According to the Genetic Polymorphism of UGT1A1 in the First Line Treatment of Metastatic Colorectal Cancer
Phase II Study: Individualization of Dosage of Irinotecan in the FOLFIRI According to the Genetic Polymorphism of UGT1A1 in the First Line Treatment of Metastatic Colorectal Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 47 (actual)
- Sponsor
- Centre Jean Perrin · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This prospective, non randomized multicenter phase II study, will determine the feasibility of individualized dose of irinotecan with the UGT1A1 polymorphism, in patients with metastatic colorectal cancer treated with FOLFIRI.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Irinotecan |
Timeline
- Start date
- 2013-10-01
- Primary completion
- 2019-12-01
- Completion
- 2019-12-09
- First posted
- 2013-10-16
- Last updated
- 2019-12-26
Locations
3 sites across 1 country: France
Source: ClinicalTrials.gov record NCT01963182. Inclusion in this directory is not an endorsement.